ClinicalTrials.gg
CompletedNCT01662063Updated Oct 12, 2016Results posted

A Long-Term Extension Study of WA22762 and NA25220 of Subcutaneous (SC) Tocilizumab (TCZ) in Moderate to Severe Rheumatoid Arthritis (RA)

A Phase 3 interventional study of Tocilizumab in Rheumatoid Arthritis, sponsored by Genentech, Inc.. Completed at 79 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-10-12.

Sponsored by Genentech, Inc. (part of Hoffmann-La Roche) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
218
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 110 studies testing tocilizumab in Arthritis, Rheumatoid — 5 open to participants now, 5 under way, none of them phase 3. tocilizumab · Arthritis, Rheumatoid.

Enrollment
30th of 110
218 · median 97
Started
2012
with 10 others
Phase 3
65 of 110
none open now
Registered
62nd of 110
by date
Lead sponsor
2 of 110
Genentech, Inc.

Among the 110 studies testing tocilizumab in Arthritis, Rheumatoid, this one is the 30th largest by enrollment, is one of 11 that started in 2012, is one of 65 in phase 3, and was the 62nd registered.

Arthritis, Rheumatoid

3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

5 of the 110 studies testing tocilizumab in Arthritis, Rheumatoid are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About tocilizumab

tocilizumab: first FDA approval 2010 (ACTEMRA), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 294 Arthritis, Rheumatoid studies recruiting now, 151 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 110 studies testing tocilizumab in Arthritis, Rheumatoid, or all of them as a file.
02

Study summary

This open-label extension study will evaluate the long-term safety and efficacy of SC TCZ in participants with moderate to severe RA who have completed the 97-week WA22762 (NCT01194414) or 96-week NA25220 (NCT01232569) core studies on SC or intravenous (IV) TCZ. Participants will receive TCZ 162 milligrams (mg) SC every week (QW) or every 2 weeks (Q2W) for up to 96 weeks.

03

Conditions studied

  • Rheumatoid Arthritis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Completed the 97-week WA22762 (NCT01194414) or 96-week NA25220 (NCT01232569) core study on SC or IV TCZ and, based on the Investigator's judgment, may continue to benefit from TCZ treatment in this study investigating the SC formulation
  • Receiving treatment on an outpatient basis
  • Females of and males with female partners of childbearing potential must agree to use reliable means of as defined by protocol

Exclusion criteria

Exclusion Criteria:

  • Premature withdrawal from WA22762 (NCT01194414) or NA25220 (NCT01232569) core studies for any reason
  • History of severe allergic or anaphylactic reactions to human, humanized, or murine monoclonal antibodies
  • Evidence of serious uncontrolled concomitant disease or disorder
  • Known active current or history of recurrent bacterial, viral, fungal, mycobacterial, or other infections
  • Any major episode of infection requiring hospitalization or treatment with IV antibiotics within 4 weeks of Screening or oral antibiotics within 2 weeks of Screening
  • History of or currently active primary or secondary immunodeficiency
  • Oral at greater than (>) 10 mg per day prednisone or equivalent, or non-steroidal anti-inflammatory drugs (NSAIDs) above the maximum recommended dose
  • Intra-articular or parenteral corticosteroids within 4 weeks prior to Baseline
  • Treatment with any or commercially available biologic disease-modifying anti-rheumatic drug (DMARD) other than TCZ at any time between completion of the core study WA22762 (NCT01194414) or NA25220 (NCT01232569) and enrollment in the long-term extension study
  • Pregnant or breastfeeding women
  • History of alcohol, drug, or chemical abuse within 1 year prior to Screening
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
218 participants (actual)

Study arms

  • Experimental
    SC TCZ QW

    Participants who received IV TCZ in the previous trial will be switched to SC TCZ 162 mg QW, and those who received SC TCZ will continue at their same dosage of SC TCZ 162 mg QW. Tocilizumab will be given for an additional 96 weeks in this open-label extension study.

    Drug: Tocilizumab

  • Experimental
    SC TCZ Q2W

    Participants who received SC TCZ will continue at their same dosage of SC TCZ 162 mg Q2W. Tocilizumab will be given for an additional 96 weeks in this open-label extension study.

    Drug: Tocilizumab

Interventions

  • TCZ will be given as 162 mg SC QW or Q2W for up to 96 weeks.

    Also known as: RoActemra/Actemra

06

What researchers measure

Primary outcomes

  1. Number of Participants With at Least One Serious Adverse Event (SAE)

    Adverse events (AEs) were monitored throughout treatment. AEs were defined as any untoward medical occurrence in a participant who received study drug regardless of causality. SAEs were defined as AEs that were fatal or life-threatening, required hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, manifested as a congenital anomaly/birth defect, were medically significant, or required intervention to prevent any of the aforementioned outcomes. The number of participants with at least one SAE regardless of treatment relationship was reported.

    Time frame: From Baseline to 8 weeks after last dose; assessed continuously during treatment (up to 96 weeks) and up to 8 weeks after last dose (up to 2 years overall)

  2. Percentage of Participants With at Least One SAE

    AEs were monitored throughout treatment. AEs were defined as any untoward medical occurrence in a participant who received study drug regardless of causality. SAEs were defined as AEs that were fatal or life-threatening, required hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, manifested as a congenital anomaly/birth defect, were medically significant, or required intervention to prevent any of the aforementioned outcomes. The percentage of participants with at least one SAE regardless of treatment relationship was calculated.

    Time frame: From Baseline to 8 weeks after last dose; assessed continuously during treatment (up to 96 weeks) and up to 8 weeks after last dose (up to 2 years overall)

  3. Percentage of Participants With a Positive Anti-TCZ Antibody Assay at Any Timepoint

    Blood samples were collected to test for the presence of antibodies to TCZ. The percentage of participants with a positive anti-TCZ antibody assay was calculated.

    Time frame: From Baseline to 8 weeks after last dose; assessed at Baseline; Weeks 12, 24, 36, 48, 60, 72, 84, 96; and up to 8 weeks after last dose (up to 2 years overall)

  4. Percentage of Participants With a Positive Anti-TCZ Antibody Assay at Baseline

    Blood samples were collected to test for the presence of antibodies to TCZ. The percentage of participants with a positive anti-TCZ antibody assay was calculated.

    Time frame: Baseline

  5. Percentage of Participants With a Positive Anti-TCZ Antibody Assay Post-Baseline

    Blood samples were collected to test for the presence of antibodies to TCZ. The percentage of participants with a positive anti-TCZ antibody assay was calculated. Positive assay results obtained post-Baseline were further investigated via confirmation assay and a neutralization assay.

    Time frame: From Week 12 up to 8 weeks after last dose; assessed at Weeks 12, 24, 36, 48, 60, 72, 84, 96; and up to 8 weeks after last dose (up to 2 years overall)

Secondary outcomes

  1. Percentage of Participants Who Correctly Administered All SC TCZ Doses

    Compliance was assessed using drug dispensing logs, diary cards kept by the participant, and return records, as reviewed by the Investigator at regular visits. Total compliance up to the end of treatment was defined as the percentage of participants who correctly administered all scheduled doses of SC TCZ. Correct administration was defined as proper injection technique, injection of the correct amount (162 mg), device not left at room temperature for greater than (\>) 8 hours, and absence of other medication errors.

    Time frame: From Baseline to last dose; assessed every 4 weeks during treatment (up to 96 weeks overall)

  2. Disease Activity Score Based on 28 Joints (DAS28) Score

    The DAS28 was calculated using the Swollen Joint Count (SJC), Tender Joint Count (TJC), erythrocyte sedimentation rate (ESR), and Global Assessment of Disease Activity by the participant according to Visual Analog Scale (VAS) score. For the DAS28 formula, the SJC and TJC values were based upon 28 joints, and VAS was transformed from a 100-millimeter (mm) scale to a 10-point score. The DAS28 was calculated as (0.56 multiplied by \[×\] square root of TJC) + (0.28 × square root of SJC) + (0.7 × log natural \[ln\] ESR) + (0.014 × VAS). Scores may range from 0 to 10, where higher scores indicate increased disease activity.

    Time frame: Baseline and Weeks 12, 24, 36, 48, 60, 72, 84

  3. Change From Baseline in DAS28 Score

    The DAS28 was calculated using the SJC, TJC, ESR, and Global Assessment of Disease Activity by the participant according to VAS score. For the DAS28 formula, the SJC and TJC values were based upon 28 joints, and VAS was transformed from a 100-mm scale to a 10-point score. The DAS28 was calculated as (0.56 × square root of TJC) + (0.28 × square root of SJC) + (0.7 × ln ESR) + (0.014 × VAS). Scores may range from 0 to 10, where higher scores indicate increased disease activity. The change from Baseline to each visit was calculated, where positive changes represent an increase or worsening in disease activity.

    Time frame: Baseline to Weeks 12, 24, 36, 48, 60, 72, 84

  4. Clinical Disease Activity Index (CDAI) Score

    The CDAI was calculated using the SJC, TJC, and Global Assessment of Disease Activity by the patient and by the physician according to separate VAS scores. For the CDAI formula, the SJC and TJC values were based upon 28 joints, and VAS was transformed from a 100-mm scale to a 10-point score. The CDAI was calculated as the sum of the component scores, that is, SJC + TJC + VAS (participant) + VAS (physician). Scores may range from 0 to 76, where higher scores indicate increased disease activity.

    Time frame: Baseline and Weeks 12, 24, 36, 48, 60, 72, 84

  5. Change From Baseline in CDAI Score

    The CDAI was calculated using the SJC, TJC, and Global Assessment of Disease Activity by the patient and by the physician according to separate VAS scores. For the CDAI formula, the SJC and TJC values were based upon 28 joints, and VAS was transformed from a 100-mm scale to a 10-point score. The CDAI was calculated as the sum of the component scores, that is, SJC + TJC + VAS (participant) + VAS (physician). Scores may range from 0 to 76, where higher scores indicate increased disease activity. The change from Baseline to each visit was calculated, where positive changes represent an increase or worsening in disease activity.

    Time frame: Baseline to Weeks 12, 24, 36, 48, 60, 72, 84

  6. Simplified Disease Activity Index (SDAI) Score

    The SDAI was calculated using the SJC, TJC, Global Assessment of Disease Activity by the patient and by the physician according to separate VAS scores, and high-sensitivity C-reactive protein (hsCRP) level. For the SDAI formula, the SJC and TJC values were based upon 28 joints, and VAS was transformed from a 100-mm scale to a 10-point score. The SDAI was calculated as the sum of the component scores, that is, SJC + TJC + VAS (participant) + VAS (physician) + hsCRP. Because the formula includes hsCRP, scores may theoretically range from 0 to infinity, where higher scores indicate increased disease activity. However, based upon normal hsCRP level within 1 milligram per deciliter (mg/dL), scores would be expected to fall within less than or equal to (≤) 77 points.

    Time frame: Baseline and Weeks 12, 24, 36, 48, 60, 72, 84

  7. Change From Baseline in SDAI Score

    The SDAI was calculated using the SJC, TJC, Global Assessment of Disease Activity by the patient and by the physician according to separate VAS scores, and hsCRP level. For the SDAI formula, the SJC and TJC values were based upon 28 joints, and VAS was transformed from a 100-mm scale to a 10-point score. The SDAI was calculated as the sum of the component scores, that is, SJC + TJC + VAS (participant) + VAS (physician) + hsCRP. Because the formula includes hsCRP, scores may theoretically range from 0 to infinity, where higher scores indicate increased disease activity. However, based upon normal hsCRP level within 1 mg/dL, scores would be expected to fall within ≤77 points. The change from Baseline to each visit was calculated, where positive changes represent an increase or worsening in disease activity.

    Time frame: Baseline to Weeks 12, 24, 36, 48, 60, 72, 84

  8. Tender Joint Count (TJC) Score

    Sixty-eight joints were assessed and classified as tender/not tender by pressure and joint manipulation on physical examination. The number of tender joints was taken as the TJC score, where values may range from 0 to 68.

    Time frame: Baseline and Weeks 12, 24, 36, 48, 60, 72, 84

  9. Change From Baseline in TJC Score

    Sixty-eight joints were assessed and classified as tender/not tender by pressure and joint manipulation on physical examination. The number of tender joints was taken as the TJC score, where values may range from 0 to 68. The change from Baseline to each visit was calculated, where positive changes represent an increase in number of tender joints.

    Time frame: Baseline to Weeks 12, 24, 36, 48, 60, 72, 84

  10. Swollen Joint Count (SJC) Score

    Sixty-six joints were assessed and classified as swollen/not swollen by pressure and joint manipulation on physical examination. The number of swollen joints was taken as the SJC score, where values may range from 0 to 66.

    Time frame: Baseline and Weeks 12, 24, 36, 48, 60, 72, 84

  11. Change From Baseline in SJC Score

    Sixty-six joints were assessed and classified as swollen/not swollen by pressure and joint manipulation on physical examination. The number of swollen joints was taken as the SJC score, where values may range from 0 to 66. The change from Baseline to each visit was calculated, where positive changes represent an increase in number of swollen joints.

    Time frame: Baseline to Weeks 12, 24, 36, 48, 60, 72, 84

  12. Number of Participants With a Disease-Modifying Anti-Rheumatic Drug (DMARD) Dose Reduction, Interruption, or Discontinuation

    Use of concomitant medications, including non-biologic DMARDs, was recorded throughout the study. Any change in DMARD therapy was documented and reported among those participants receiving at least one DMARD at Baseline.

    Time frame: From Baseline to last dose; assessed every 4 weeks during treatment (up to 96 weeks overall)

  13. Percentage of Participants With a DMARD Dose Reduction, Interruption, or Discontinuation

    Use of concomitant medications, including non-biologic DMARDs, was recorded throughout the study. Any change in DMARD therapy was documented and reported among those participants receiving at least one DMARD at Baseline.

    Time frame: From Baseline to last dose; assessed every 4 weeks during treatment (up to 96 weeks overall)

  14. Percentage of Reasons Given for DMARD Dose Reduction or Interruption

    Use of concomitant medications, including non-biologic DMARDs, was recorded throughout the study. Any change in DMARD therapy was documented and reported among those participants receiving at least one DMARD at Baseline. The reasons for any DMARD dose reduction/interruption ≤60 days were reported. More than one reason could be given for a single change in DMARD therapy, and each participant could also change DMARD therapy more than once. Therefore, the number of reasons could exceed the number of participants analyzed.

    Time frame: From Baseline to last dose; assessed every 4 weeks during treatment (up to 96 weeks overall)

  15. Percentage of Reasons Given for DMARD Discontinuation

    Use of concomitant medications, including non-biologic DMARDs, was recorded throughout the study. Any change in DMARD therapy was documented and reported among those participants receiving at least one DMARD at Baseline. The reasons for any DMARD discontinuation were reported. More than one reason could be given for a single change in DMARD therapy, and each participant could also change DMARD therapy more than once. Therefore, the number of reasons could exceed the number of participants analyzed.

    Time frame: From Baseline to last dose; assessed every 4 weeks during treatment (up to 96 weeks overall)

  16. Number of Participants With a Corticosteroid (CCS) Dose Reduction, Interruption, or Discontinuation

    Use of concomitant medications, including CCS treatment, was recorded throughout the study. Any change in CCS therapy was documented and reported among those participants who received at least one CCS before the last dose of SC TCZ.

    Time frame: From Baseline to last dose; assessed every 4 weeks during treatment (up to 96 weeks overall)

  17. Percentage of Participants With a CCS Dose Reduction, Interruption, or Discontinuation

    Use of concomitant medications, including CCS treatment, was recorded throughout the study. Any change in CCS therapy was documented and reported among those participants who received at least one CCS before the last dose of SC TCZ.

    Time frame: From Baseline to last dose; assessed every 4 weeks during treatment (up to 96 weeks overall)

  18. Percentage of Reasons Given for CCS Dose Reduction

    Use of concomitant medications, including CCS treatment, was recorded throughout the study. Any change in CCS therapy was documented and reported among those participants who received at least one CCS before the last dose of SC TCZ. The reasons for any CCS dose reduction were reported. More than one reason could be given for a single change in CCS therapy, and each participant could also change CCS therapy more than once. Therefore, the number of reasons could exceed the number of participants analyzed.

    Time frame: From Baseline to last dose; assessed every 4 weeks during treatment (up to 96 weeks overall)

  19. Percentage of Reasons Given for CCS Dose Interruption

    Use of concomitant medications, including CCS treatment, was recorded throughout the study. Any change in CCS therapy was documented and reported among those participants who received at least one CCS before the last dose of SC TCZ. The reasons for any CCS dose interruption ≤14 days were reported. More than one reason could be given for a single change in CCS therapy, and each participant could also change CCS therapy more than once. Therefore, the number of reasons could exceed the number of participants analyzed.

    Time frame: From Baseline to last dose; assessed every 4 weeks during treatment (up to 96 weeks overall)

  20. Percentage of Reasons Given for CCS Discontinuation

    Use of concomitant medications, including CCS treatment, was recorded throughout the study. Any change in CCS therapy was documented and reported among those participants who received at least one CCS before the last dose of SC TCZ. The reasons for any CCS discontinuation \>14 days were reported. More than one reason could be given for a single change in CCS therapy, and each participant could also change CCS therapy more than once. Therefore, the number of reasons could exceed the number of participants analyzed.

    Time frame: From Baseline to last dose; assessed every 4 weeks during treatment (up to 96 weeks overall)

  21. Number of Participants Who Switched From the QW Regimen and Remained on the Q2W Regimen

    Participants could switch between regimens at the Investigator's judgment based upon safety, efficacy, and pharmacokinetic/pharmacodynamic data. The number of participants who switched from the QW to the Q2W regimen and did not return to the QW regimen was reported.

    Time frame: From Baseline to last dose; assessed every 4 weeks during treatment (up to 96 weeks overall)

  22. Percentage of Participants Who Switched From the QW Regimen and Remained on the Q2W Regimen

    Participants could switch between regimens at the Investigator's judgment based upon safety, efficacy, and pharmacokinetic/pharmacodynamic data. The percentage of participants who switched from the QW to the Q2W regimen and did not return to the QW regimen was calculated.

    Time frame: From Baseline to last dose; assessed every 4 weeks during treatment (up to 96 weeks overall)

  23. Number of Participants Who Returned to the QW Regimen After Switching to the Q2W Regimen

    Participants could switch between regimens at the Investigator's judgment based upon safety, efficacy, and pharmacokinetic/pharmacodynamic data. The number of participants who switched from the QW to the Q2W regimen and thereafter returned to the QW regimen was reported with the reason for returning to the QW regimen.

    Time frame: From Baseline to last dose; assessed every 4 weeks during treatment (up to 96 weeks overall)

  24. Time to Return to the QW Regimen After Switching to the Q2W Regimen

    Participants could switch between regimens at the Investigator's judgment based upon safety, efficacy, and pharmacokinetic/pharmacodynamic data. Time to return was defined as the time between switching to the Q2W regimen and returning to the previous QW regimen.

    Time frame: From Baseline to last dose; assessed every 4 weeks during treatment (up to 96 weeks overall)

  25. Global Assessment of Disease Activity by the Participant According to Visual Analog Scale (VAS) Score

    The Global Assessment of Disease Activity was performed using a 100-mm horizontal VAS. Scores may range from 0 mm ("no disease activity") to 100 mm ("maximum disease activity"), with higher scores representing an increase in perceived symptoms.

    Time frame: Baseline and Weeks 12, 24, 36, 48, 60, 72, 84

  26. Change From Baseline in Global Assessment of Disease Activity by the Participant According to VAS Score

    The Global Assessment of Disease Activity was performed using a 100-mm horizontal VAS. Scores may range from 0 mm ("no disease activity") to 100 mm ("maximum disease activity"), with higher scores representing an increase in perceived symptoms. The change from Baseline to each visit was calculated, where positive changes represent an increase or worsening in perceived disease activity.

    Time frame: Baseline to Weeks 12, 24, 36, 48, 60, 72, 84

  27. Global Assessment of Pain by the Participant According to VAS Score

    The Global Assessment of Pain was performed using a 100-mm horizontal VAS. Scores may range from 0 mm ("no pain") to 100 mm ("unbearable pain"), with higher scores representing an increase in pain.

    Time frame: Baseline and Weeks 12, 24, 36, 48, 60, 72, 84

  28. Change From Baseline in Global Assessment of Pain by the Participant According to VAS Score

    The Global Assessment of Pain was performed using a 100-mm horizontal VAS. Scores may range from 0 mm ("no pain") to 100 mm ("unbearable pain"), with higher scores representing an increase in pain. The change from Baseline to each visit was calculated, where positive changes represent an increase or worsening in pain.

    Time frame: Baseline to Weeks 12, 24, 36, 48, 60, 72, 84

  29. Heath Assessment Questionnaire-Disability Index (HAQ-DI) Score

    The Stanford HAQ-DI was calculated as the average of 20 questions, each scored from 0 (no difficulty) to 3 (unable to do). The questionnaire included 8 component sets: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and common activities. Overall scores may range from 0 to 3, with higher scores representing increased disability.

    Time frame: Baseline and Weeks 12, 24, 36, 48, 60, 72, 84

  30. Change From Baseline in HAQ-DI Score

    The Stanford HAQ-DI was calculated as the average of 20 questions, each scored from 0 (no difficulty) to 3 (unable to do). The questionnaire included 8 component sets: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and common activities. Overall scores may range from 0 to 3, with higher scores representing increased disability. The change from Baseline to each visit was calculated, where positive changes represent an increased need for assistance with daily activities.

    Time frame: Baseline to Weeks 12, 24, 36, 48, 60, 72, 84

  31. Percentage of Participants With HAQ-DI Score <0.5

    The Stanford HAQ-DI was calculated as the average of 20 questions, each scored from 0 (no difficulty) to 3 (unable to do). The questionnaire included 8 component sets: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and common activities. Overall scores may range from 0 to 3, with higher scores representing increased disability. The percentage of participants achieving a score \<0.5 was calculated at each visit.

    Time frame: Baseline and Weeks 12, 24, 36, 48, 60, 72, 84

  32. Number of Participants With Low Disease Activity According to DAS28, SDAI, and CDAI Criteria

    Low disease activity was defined as DAS28 ≤3.2, SDAI ≤11, or CDAI ≤10. For each formula, the SJC and TJC values were based upon 28 joints, and VAS was transformed from a 100-mm scale to a 10-point score. The DAS28 was calculated as (0.56 × square root of TJC) + (0.28 × square root of SJC) + (0.7 × ln ESR) + (0.014 × VAS), with potential scores from 0 to 10. The SDAI was calculated as SJC + TJC + VAS (participant) + VAS (physician) + hsCRP, with potential scores from 0 to infinity. However, based upon normal hsCRP level within 1 mg/dL, scores would be expected to fall within ≤77 points. The CDAI was calculated as SJC + TJC + VAS (participant) + VAS (physician), with potential scores from 0 to 76. For all instruments, higher scores indicate increased disease activity. The number of participants who met criteria for low disease activity was reported at each visit.

    Time frame: Baseline and Weeks 12, 24, 36, 48, 60, 72, 84

  33. Percentage of Participants With Low Disease Activity According to DAS28, SDAI, and CDAI Criteria

    Low disease activity was defined as DAS28 ≤3.2, SDAI ≤11, or CDAI ≤10. For each formula, the SJC and TJC values were based upon 28 joints, and VAS was transformed from a 100-mm scale to a 10-point score. The DAS28 was calculated as (0.56 × square root of TJC) + (0.28 × square root of SJC) + (0.7 × ln ESR) + (0.014 × VAS), with potential scores from 0 to 10. The SDAI was calculated as SJC + TJC + VAS (participant) + VAS (physician) + hsCRP, with potential scores from 0 to infinity. However, based upon normal hsCRP level within 1 mg/dL, scores would be expected to fall within ≤77 points. The CDAI was calculated as SJC + TJC + VAS (participant) + VAS (physician), with potential scores from 0 to 76. For all instruments, higher scores indicate increased disease activity. The percentage of participants who met criteria for low disease activity was calculated at each visit.

    Time frame: Baseline and Weeks 12, 24, 36, 48, 60, 72, 84

  34. Number of Participants With Remission According to DAS28, SDAI, and Boolean Criteria

    Remission was defined as DAS28 \<2.6, SDAI ≤3.3, or meeting all Boolean criteria (28-count SJC and TJC ≤1, VAS ≤10 mm, and hsCRP ≤1 mg/dL). For DAS28 and SDAI formulas, the SJC and TJC values were based upon 28 joints, and VAS was transformed from a 100-mm scale to a 10-point score. The DAS28 was calculated as (0.56 × square root of TJC) + (0.28 × square root of SJC) + (0.7 × ln ESR) + (0.014 × VAS), with potential scores from 0 to 10. The SDAI was calculated as SJC + TJC + VAS (participant) + VAS (physician) + hsCRP, with potential scores from 0 to infinity. However, based upon normal hsCRP level within 1 mg/dL, scores would be expected to fall within ≤77 points. For these instruments, higher scores indicate increased disease activity. The number of participants who met criteria for remission was reported at each visit.

    Time frame: Baseline and Weeks 12, 24, 36, 48, 60, 72, 84

  35. Percentage of Participants With Remission According to DAS28, SDAI, and Boolean Criteria

    Remission was defined as DAS28 \<2.6, SDAI ≤3.3, or meeting all Boolean criteria (28-count SJC and TJC ≤1, VAS ≤10 mm, and hsCRP ≤1 mg/dL). For DAS28 and SDAI formulas, the SJC and TJC values were based upon 28 joints, and VAS was transformed from a 100-mm scale to a 10-point score. The DAS28 was calculated as (0.56 × square root of TJC) + (0.28 × square root of SJC) + (0.7 × ln ESR) + (0.014 × VAS), with potential scores from 0 to 10. The SDAI was calculated as SJC + TJC + VAS (participant) + VAS (physician) + hsCRP, with potential scores from 0 to infinity. However, based upon normal hsCRP level within 1 mg/dL, scores would be expected to fall within ≤77 points. For these instruments, higher scores indicate increased disease activity. The percentage of participants who met criteria for remission was calculated at each visit.

    Time frame: Baseline and Weeks 12, 24, 36, 48, 60, 72, 84

07

Results

Posted Oct 12, 2016

Participant flow

Participant flow — Overall Study
MilestoneSubcutaneous (SC) Tocilizumab (TCZ) Every 2 Weeks (Q2W)SC TCZ Every Week (QW)Not Treated
Started441731
Completed391440
Not completed5291
Withdrew: Adverse event or intercurrent illness1120
Withdrew: Lack of efficacy160
Withdrew: Lost to follow-up040
Withdrew: Protocol violation100
Withdrew: Withdrawal by subject241
Withdrew: Physician decision020
Withdrew: Other010

Outcome measures

PrimaryNumber of Participants With at Least One Serious Adverse Event (SAE)

Adverse events (AEs) were monitored throughout treatment. AEs were defined as any untoward medical occurrence in a participant who received study drug regardless of causality. SAEs were defined as AEs that were fatal or life-threatening, required hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, manifested as a congenital anomaly/birth defect, were medically significant, or required intervention to prevent any of the aforementioned outcomes. The number of participants with at least one SAE regardless of treatment relationship was reported.

Time frame:
From Baseline to 8 weeks after last dose; assessed continuously during treatment (up to 96 weeks) and up to 8 weeks after last dose (up to 2 years overall)
Reported as:
Number · participants
Number of Participants With at Least One Serious Adverse Event (SAE)
participantsSC TCZ Q2WSC TCZ QW
Number of Participants With at Least One Serious Adverse Event (SAE)419
PrimaryPercentage of Participants With at Least One SAE

AEs were monitored throughout treatment. AEs were defined as any untoward medical occurrence in a participant who received study drug regardless of causality. SAEs were defined as AEs that were fatal or life-threatening, required hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, manifested as a congenital anomaly/birth defect, were medically significant, or required intervention to prevent any of the aforementioned outcomes. The percentage of participants with at least one SAE regardless of treatment relationship was calculated.

Time frame:
From Baseline to 8 weeks after last dose; assessed continuously during treatment (up to 96 weeks) and up to 8 weeks after last dose (up to 2 years overall)
Reported as:
Number · percentage of participants
Percentage of Participants With at Least One SAE
percentage of participantsSC TCZ Q2WSC TCZ QW
Percentage of Participants With at Least One SAE9.111.0
PrimaryPercentage of Participants With a Positive Anti-TCZ Antibody Assay at Any Timepoint

Blood samples were collected to test for the presence of antibodies to TCZ. The percentage of participants with a positive anti-TCZ antibody assay was calculated.

Time frame:
From Baseline to 8 weeks after last dose; assessed at Baseline; Weeks 12, 24, 36, 48, 60, 72, 84, 96; and up to 8 weeks after last dose (up to 2 years overall)
Reported as:
Number · percentage of participants
Percentage of Participants With a Positive Anti-TCZ Antibody Assay at Any Timepoint
percentage of participantsSC TCZ Q2WSC TCZ QW
Percentage of Participants With a Positive Anti-TCZ Antibody Assay at Any Timepoint4.57.8
PrimaryPercentage of Participants With a Positive Anti-TCZ Antibody Assay at Baseline

Blood samples were collected to test for the presence of antibodies to TCZ. The percentage of participants with a positive anti-TCZ antibody assay was calculated.

Time frame:
Baseline
Reported as:
Number · percentage of participants
Percentage of Participants With a Positive Anti-TCZ Antibody Assay at Baseline
percentage of participantsSC TCZ Q2WSC TCZ QW
Percentage of Participants With a Positive Anti-TCZ Antibody Assay at Baseline2.34.8
PrimaryPercentage of Participants With a Positive Anti-TCZ Antibody Assay Post-Baseline

Blood samples were collected to test for the presence of antibodies to TCZ. The percentage of participants with a positive anti-TCZ antibody assay was calculated. Positive assay results obtained post-Baseline were further investigated via confirmation assay and a neutralization assay.

Time frame:
From Week 12 up to 8 weeks after last dose; assessed at Weeks 12, 24, 36, 48, 60, 72, 84, 96; and up to 8 weeks after last dose (up to 2 years overall)
Reported as:
Number · percentage of participants
Percentage of Participants With a Positive Anti-TCZ Antibody Assay Post-Baseline
percentage of participantsSC TCZ Q2WSC TCZ QW
Positive Anti-TCZ Assay2.33.0
Positive Confirmation Assay00.6
Positive Neutralizing Assay00.6
SecondaryPercentage of Participants Who Correctly Administered All SC TCZ Doses

Compliance was assessed using drug dispensing logs, diary cards kept by the participant, and return records, as reviewed by the Investigator at regular visits. Total compliance up to the end of treatment was defined as the percentage of participants who correctly administered all scheduled doses of SC TCZ. Correct administration was defined as proper injection technique, injection of the correct amount (162 mg), device not left at room temperature for greater than (\>) 8 hours, and absence of other medication errors.

Time frame:
From Baseline to last dose; assessed every 4 weeks during treatment (up to 96 weeks overall)
Reported as:
Number · percentage of participants
Percentage of Participants Who Correctly Administered All SC TCZ Doses
percentage of participantsSC TCZ Q2WSC TCZ QW
Percentage of Participants Who Correctly Administered All SC TCZ Doses97.797.7
SecondaryDisease Activity Score Based on 28 Joints (DAS28) Score

The DAS28 was calculated using the Swollen Joint Count (SJC), Tender Joint Count (TJC), erythrocyte sedimentation rate (ESR), and Global Assessment of Disease Activity by the participant according to Visual Analog Scale (VAS) score. For the DAS28 formula, the SJC and TJC values were based upon 28 joints, and VAS was transformed from a 100-millimeter (mm) scale to a 10-point score. The DAS28 was calculated as (0.56 multiplied by \[×\] square root of TJC) + (0.28 × square root of SJC) + (0.7 × log natural \[ln\] ESR) + (0.014 × VAS). Scores may range from 0 to 10, where higher scores indicate increased disease activity.

Time frame:
Baseline and Weeks 12, 24, 36, 48, 60, 72, 84
Reported as:
Mean · units on a scale
Disease Activity Score Based on 28 Joints (DAS28) Score
units on a scaleSC TCZ Q2WSC TCZ QW
Baseline (n=44,172)4.55 ± 1.7324.60 ± 1.869
Week 12 (n=44,172)3.17 ± 1.4433.42 ± 1.728
Week 24 (n=43,168)3.08 ± 1.3513.35 ± 1.786
Week 36 (n=39,159)3.07 ± 1.4253.29 ± 1.624
Week 48 (n=18,141)3.15 ± 1.3923.25 ± 1.639
Week 60 (n=2,92)4.10 ± 0.5153.12 ± 1.626
Week 72 (n=1,52)5.76 ± NA3.05 ± 1.970
Week 84 (n=0,11)NA ± NA2.78 ± 1.434
SecondaryChange From Baseline in DAS28 Score

The DAS28 was calculated using the SJC, TJC, ESR, and Global Assessment of Disease Activity by the participant according to VAS score. For the DAS28 formula, the SJC and TJC values were based upon 28 joints, and VAS was transformed from a 100-mm scale to a 10-point score. The DAS28 was calculated as (0.56 × square root of TJC) + (0.28 × square root of SJC) + (0.7 × ln ESR) + (0.014 × VAS). Scores may range from 0 to 10, where higher scores indicate increased disease activity. The change from Baseline to each visit was calculated, where positive changes represent an increase or worsening in disease activity.

Time frame:
Baseline to Weeks 12, 24, 36, 48, 60, 72, 84
Reported as:
Mean · units on a scale
Change From Baseline in DAS28 Score
units on a scaleSC TCZ Q2WSC TCZ QW
Week 12 (n=44,171)-1.38 ± 1.522-1.19 ± 1.415
Week 24 (n=43,167)-1.42 ± 1.383-1.23 ± 1.692
Week 36 (n=39,158)-1.51 ± 1.312-1.29 ± 1.429
Week 48 (n=18,140)-1.66 ± 1.340-1.32 ± 1.538
Week 60 (n=2,91)0.65 ± 1.410-1.29 ± 1.286
Week 72 (n=1,52)-0.35 ± NA-1.53 ± 1.435
Week 84 (n=0,10)NA ± NA-1.57 ± 1.312
SecondaryClinical Disease Activity Index (CDAI) Score

The CDAI was calculated using the SJC, TJC, and Global Assessment of Disease Activity by the patient and by the physician according to separate VAS scores. For the CDAI formula, the SJC and TJC values were based upon 28 joints, and VAS was transformed from a 100-mm scale to a 10-point score. The CDAI was calculated as the sum of the component scores, that is, SJC + TJC + VAS (participant) + VAS (physician). Scores may range from 0 to 76, where higher scores indicate increased disease activity.

Time frame:
Baseline and Weeks 12, 24, 36, 48, 60, 72, 84
Reported as:
Mean · units on a scale
Clinical Disease Activity Index (CDAI) Score
units on a scaleSC TCZ Q2WSC TCZ QW
Baseline (n=44,173)20.10 ± 15.46723.91 ± 16.346
Week 12 (n=44,172)13.99 ± 13.05818.19 ± 14.145
Week 24 (n=42,166)14.86 ± 13.23218.03 ± 13.665
Week 36 (n=39,159)13.26 ± 11.83916.92 ± 12.598
Week 48 (n=18,140)15.81 ± 16.47916.55 ± 13.559
Week 60 (n=2,92)13.60 ± 2.82814.71 ± 11.954
Week 72 (n=1,52)27.80 ± NA16.04 ± 15.476
Week 84 (n=0,11)NA ± NA12.82 ± 9.154
SecondaryChange From Baseline in CDAI Score

The CDAI was calculated using the SJC, TJC, and Global Assessment of Disease Activity by the patient and by the physician according to separate VAS scores. For the CDAI formula, the SJC and TJC values were based upon 28 joints, and VAS was transformed from a 100-mm scale to a 10-point score. The CDAI was calculated as the sum of the component scores, that is, SJC + TJC + VAS (participant) + VAS (physician). Scores may range from 0 to 76, where higher scores indicate increased disease activity. The change from Baseline to each visit was calculated, where positive changes represent an increase or worsening in disease activity.

Time frame:
Baseline to Weeks 12, 24, 36, 48, 60, 72, 84
Reported as:
Mean · units on a scale
Change From Baseline in CDAI Score
units on a scaleSC TCZ Q2WSC TCZ QW
Week 12 (n=44,172)-6.11 ± 13.219-5.81 ± 12.010
Week 24 (n=42,166)-5.23 ± 14.134-5.47 ± 13.754
Week 36 (n=39,159)-7.00 ± 12.266-6.63 ± 10.676
Week 48 (n=18,140)-6.63 ± 13.479-6.70 ± 12.328
Week 60 (n=2,92)-14.05 ± 20.294-7.05 ± 11.065
Week 72 (n=1,52)-16.20 ± NA-6.31 ± 12.999
Week 84 (n=0,11)NA ± NA-10.01 ± 18.580
SecondarySimplified Disease Activity Index (SDAI) Score

The SDAI was calculated using the SJC, TJC, Global Assessment of Disease Activity by the patient and by the physician according to separate VAS scores, and high-sensitivity C-reactive protein (hsCRP) level. For the SDAI formula, the SJC and TJC values were based upon 28 joints, and VAS was transformed from a 100-mm scale to a 10-point score. The SDAI was calculated as the sum of the component scores, that is, SJC + TJC + VAS (participant) + VAS (physician) + hsCRP. Because the formula includes hsCRP, scores may theoretically range from 0 to infinity, where higher scores indicate increased disease activity. However, based upon normal hsCRP level within 1 milligram per deciliter (mg/dL), scores would be expected to fall within less than or equal to (≤) 77 points.

Time frame:
Baseline and Weeks 12, 24, 36, 48, 60, 72, 84
Reported as:
Mean · units on a scale
Simplified Disease Activity Index (SDAI) Score
units on a scaleSC TCZ Q2WSC TCZ QW
Baseline (n=44,170)21.54 ± 15.71725.10 ± 16.972
Week 12 (n=44,172)14.48 ± 13.05818.32 ± 14.199
Week 24 (n=41,166)15.42 ± 13.26618.18 ± 13.779
Week 36 (n=39,159)13.75 ± 11.84117.06 ± 12.621
Week 48 (n=18,140)15.85 ± 16.49016.76 ± 13.603
Week 60 (n=2,92)13.63 ± 2.84114.90 ± 12.045
Week 72 (n=1,52)27.82 ± NA16.23 ± 15.730
Week 84 (n=0,11)NA ± NA12.90 ± 9.163
SecondaryChange From Baseline in SDAI Score

The SDAI was calculated using the SJC, TJC, Global Assessment of Disease Activity by the patient and by the physician according to separate VAS scores, and hsCRP level. For the SDAI formula, the SJC and TJC values were based upon 28 joints, and VAS was transformed from a 100-mm scale to a 10-point score. The SDAI was calculated as the sum of the component scores, that is, SJC + TJC + VAS (participant) + VAS (physician) + hsCRP. Because the formula includes hsCRP, scores may theoretically range from 0 to infinity, where higher scores indicate increased disease activity. However, based upon normal hsCRP level within 1 mg/dL, scores would be expected to fall within ≤77 points. The change from Baseline to each visit was calculated, where positive changes represent an increase or worsening in disease activity.

Time frame:
Baseline to Weeks 12, 24, 36, 48, 60, 72, 84
Reported as:
Mean · units on a scale
Change From Baseline in SDAI Score
units on a scaleSC TCZ Q2WSC TCZ QW
Week 12 (n=44,169)-7.07 ± 13.671-7.00 ± 12.056
Week 24 (n=41,163)-5.71 ± 14.217-6.79 ± 13.069
Week 36 (n=39,157)-7.99 ± 12.858-7.38 ± 10.953
Week 48 (n=18,139)-8.17 ± 14.640-7.29 ± 12.454
Week 60 (n=2,91)-14.46 ± 20.873-7.52 ± 10.846
Week 72 (n=1,52)-17.04 ± NA-7.10 ± 13.379
Week 84 (n=0,10)NA ± NA-9.48 ± 19.290
SecondaryTender Joint Count (TJC) Score

Sixty-eight joints were assessed and classified as tender/not tender by pressure and joint manipulation on physical examination. The number of tender joints was taken as the TJC score, where values may range from 0 to 68.

Time frame:
Baseline and Weeks 12, 24, 36, 48, 60, 72, 84
Reported as:
Mean · tender joints
Tender Joint Count (TJC) Score
tender jointsSC TCZ Q2WSC TCZ QW
Baseline (n=44,173)13.84 ± 13.88319.14 ± 18.469
Week 12 (n=44,172)9.86 ± 11.72714.06 ± 14.874
Week 24 (n=42,167)10.95 ± 14.22113.86 ± 15.176
Week 36 (n=39,159)9.10 ± 11.39213.45 ± 14.398
Week 48 (n=18,141)10.61 ± 14.82512.85 ± 16.192
Week 60 (n=2,92)5.50 ± 0.70710.47 ± 12.589
Week 72 (n=1,52)21.00 ± NA11.38 ± 15.444
Week 84 (n=0,11)NA ± NA9.36 ± 10.984
SecondaryChange From Baseline in TJC Score

Sixty-eight joints were assessed and classified as tender/not tender by pressure and joint manipulation on physical examination. The number of tender joints was taken as the TJC score, where values may range from 0 to 68. The change from Baseline to each visit was calculated, where positive changes represent an increase in number of tender joints.

Time frame:
Baseline to Weeks 12, 24, 36, 48, 60, 72, 84
Reported as:
Mean · tender joints
Change From Baseline in TJC Score
tender jointsSC TCZ Q2WSC TCZ QW
Week 12 (n=44,172)-3.98 ± 12.082-5.17 ± 12.175
Week 24 (n=42,167)-2.69 ± 12.546-5.12 ± 14.817
Week 36 (n=39,159)-4.03 ± 10.559-5.60 ± 12.402
Week 48 (n=18,141)-4.00 ± 12.902-5.95 ± 13.899
Week 60 (n=2,92)-9.00 ± 12.728-6.23 ± 10.672
Week 72 (n=1,52)-3.00 ± NA-4.98 ± 11.514
Week 84 (n=0,11)NA ± NA-6.27 ± 13.835
SecondarySwollen Joint Count (SJC) Score

Sixty-six joints were assessed and classified as swollen/not swollen by pressure and joint manipulation on physical examination. The number of swollen joints was taken as the SJC score, where values may range from 0 to 66.

Time frame:
Baseline and Weeks 12, 24, 36, 48, 60, 72, 84
Reported as:
Mean · swollen joints
Swollen Joint Count (SJC) Score
swollen jointsSC TCZ Q2WSC TCZ QW
Baseline (n=44,173)9.07 ± 8.87710.83 ± 10.855
Week 12 (n=44,172)5.61 ± 7.1447.87 ± 8.839
Week 24 (n=42,167)5.98 ± 8.5878.57 ± 8.783
Week 36 (n=39,159)5.51 ± 8.3986.92 ± 7.055
Week 48 (n=18,141)4.78 ± 9.0787.23 ± 7.870
Week 60 (n=2,92)2.00 ± 2.8286.52 ± 7.184
Week 72 (n=1,52)2.00 ± NA7.98 ± 8.873
Week 84 (n=0,11)NA ± NA8.64 ± 8.857
SecondaryChange From Baseline in SJC Score

Sixty-six joints were assessed and classified as swollen/not swollen by pressure and joint manipulation on physical examination. The number of swollen joints was taken as the SJC score, where values may range from 0 to 66. The change from Baseline to each visit was calculated, where positive changes represent an increase in number of swollen joints.

Time frame:
Baseline to Weeks 12, 24, 36, 48, 60, 72, 84
Reported as:
Mean · swollen joints
Change From Baseline in SJC Score
swollen jointsSC TCZ Q2WSC TCZ QW
Week 12 (n=44,172)-3.45 ± 7.026-3.00 ± 8.543
Week 24 (n=42,167)-3.45 ± 8.434-2.31 ± 9.162
Week 36 (n=39,159)-3.33 ± 6.868-3.89 ± 8.134
Week 48 (n=18,141)-6.56 ± 9.332-3.25 ± 9.543
Week 60 (n=2,92)-8.50 ± 12.021-3.20 ± 8.702
Week 72 (n=1,52)-15.00 ± NA-1.15 ± 10.114
Week 84 (n=0,11)NA ± NA-2.64 ± 13.493
SecondaryNumber of Participants With a Disease-Modifying Anti-Rheumatic Drug (DMARD) Dose Reduction, Interruption, or Discontinuation

Use of concomitant medications, including non-biologic DMARDs, was recorded throughout the study. Any change in DMARD therapy was documented and reported among those participants receiving at least one DMARD at Baseline.

Time frame:
From Baseline to last dose; assessed every 4 weeks during treatment (up to 96 weeks overall)
Reported as:
Number · participants
Number of Participants With a Disease-Modifying Anti-Rheumatic Drug (DMARD) Dose Reduction, Interruption, or Discontinuation
participantsSC TCZ Q2WSC TCZ QW
Any Dose Reduction/Interruption/Discontinuation337
Dose Reduction114
Dose Interruption ≤60 Days115
Dose Reduction/Interruption ≤60 Days127
Discontinuation >60 Days215
SecondaryPercentage of Participants With a DMARD Dose Reduction, Interruption, or Discontinuation

Use of concomitant medications, including non-biologic DMARDs, was recorded throughout the study. Any change in DMARD therapy was documented and reported among those participants receiving at least one DMARD at Baseline.

Time frame:
From Baseline to last dose; assessed every 4 weeks during treatment (up to 96 weeks overall)
Reported as:
Number · percentage of participants
Percentage of Participants With a DMARD Dose Reduction, Interruption, or Discontinuation
percentage of participantsSC TCZ Q2WSC TCZ QW
Any Dose Reduction/Interruption/Discontinuation7.323.0
Dose Reduction2.48.7
Dose Interruption ≤60 Days2.49.3
Dose Reduction/Interruption ≤60 Days2.416.8
Discontinuation >60 Days4.99.3
SecondaryPercentage of Reasons Given for DMARD Dose Reduction or Interruption

Use of concomitant medications, including non-biologic DMARDs, was recorded throughout the study. Any change in DMARD therapy was documented and reported among those participants receiving at least one DMARD at Baseline. The reasons for any DMARD dose reduction/interruption ≤60 days were reported. More than one reason could be given for a single change in DMARD therapy, and each participant could also change DMARD therapy more than once. Therefore, the number of reasons could exceed the number of participants analyzed.

Time frame:
From Baseline to last dose; assessed every 4 weeks during treatment (up to 96 weeks overall)
Reported as:
Number · percentage of reasons
Percentage of Reasons Given for DMARD Dose Reduction or Interruption
percentage of reasonsSC TCZ Q2WSC TCZ QW
AEs070.7
Efficacy02.4
Joint Surgery02.4
Medical History100.02.4
RA Improvement07.3
RA Treatment02.4
Replace Previous Drug02.4
Participant Request02.4
Not Specified07.3
SecondaryPercentage of Reasons Given for DMARD Discontinuation

Use of concomitant medications, including non-biologic DMARDs, was recorded throughout the study. Any change in DMARD therapy was documented and reported among those participants receiving at least one DMARD at Baseline. The reasons for any DMARD discontinuation were reported. More than one reason could be given for a single change in DMARD therapy, and each participant could also change DMARD therapy more than once. Therefore, the number of reasons could exceed the number of participants analyzed.

Time frame:
From Baseline to last dose; assessed every 4 weeks during treatment (up to 96 weeks overall)
Reported as:
Number · percentage of reasons
Percentage of Reasons Given for DMARD Discontinuation
percentage of reasonsSC TCZ Q2WSC TCZ QW
AEs66.743.8
Efficacy33.30
Investigator Recommendation06.3
RA Improvement031.3
Participant Request06.3
Too Expensive06.3
Not Specified06.3
SecondaryNumber of Participants With a Corticosteroid (CCS) Dose Reduction, Interruption, or Discontinuation

Use of concomitant medications, including CCS treatment, was recorded throughout the study. Any change in CCS therapy was documented and reported among those participants who received at least one CCS before the last dose of SC TCZ.

Time frame:
From Baseline to last dose; assessed every 4 weeks during treatment (up to 96 weeks overall)
Reported as:
Number · participants
Number of Participants With a Corticosteroid (CCS) Dose Reduction, Interruption, or Discontinuation
participantsSC TCZ Q2WSC TCZ QW
Any Dose Reduction/Interruption/Discontinuation633
Dose Reduction524
Dose Interruption ≤14 Days02
Discontinuation >14 Days219
SecondaryPercentage of Participants With a CCS Dose Reduction, Interruption, or Discontinuation

Use of concomitant medications, including CCS treatment, was recorded throughout the study. Any change in CCS therapy was documented and reported among those participants who received at least one CCS before the last dose of SC TCZ.

Time frame:
From Baseline to last dose; assessed every 4 weeks during treatment (up to 96 weeks overall)
Reported as:
Number · percentage of participants
Percentage of Participants With a CCS Dose Reduction, Interruption, or Discontinuation
percentage of participantsSC TCZ Q2WSC TCZ QW
Any Dose Reduction/Interruption/Discontinuation40.037.1
Dose Reduction33.327.0
Dose Interruption ≤14 Days02.2
Discontinuation >14 Days13.321.3
SecondaryPercentage of Reasons Given for CCS Dose Reduction

Use of concomitant medications, including CCS treatment, was recorded throughout the study. Any change in CCS therapy was documented and reported among those participants who received at least one CCS before the last dose of SC TCZ. The reasons for any CCS dose reduction were reported. More than one reason could be given for a single change in CCS therapy, and each participant could also change CCS therapy more than once. Therefore, the number of reasons could exceed the number of participants analyzed.

Time frame:
From Baseline to last dose; assessed every 4 weeks during treatment (up to 96 weeks overall)
Reported as:
Number · percentage of reasons
Percentage of Reasons Given for CCS Dose Reduction
percentage of reasonsSC TCZ Q2WSC TCZ QW
AEs03.6
Medical History42.90
RA Treatment02.4
Steroid Tapering50.091.7
Participant Request01.2
Not Specified7.11.2
SecondaryPercentage of Reasons Given for CCS Dose Interruption

Use of concomitant medications, including CCS treatment, was recorded throughout the study. Any change in CCS therapy was documented and reported among those participants who received at least one CCS before the last dose of SC TCZ. The reasons for any CCS dose interruption ≤14 days were reported. More than one reason could be given for a single change in CCS therapy, and each participant could also change CCS therapy more than once. Therefore, the number of reasons could exceed the number of participants analyzed.

Time frame:
From Baseline to last dose; assessed every 4 weeks during treatment (up to 96 weeks overall)
Reported as:
Number · percentage of reasons
Percentage of Reasons Given for CCS Dose Interruption
percentage of reasonsSC TCZ QW
Hospitalization33.3
Steroid Tapering66.7
SecondaryPercentage of Reasons Given for CCS Discontinuation

Use of concomitant medications, including CCS treatment, was recorded throughout the study. Any change in CCS therapy was documented and reported among those participants who received at least one CCS before the last dose of SC TCZ. The reasons for any CCS discontinuation \>14 days were reported. More than one reason could be given for a single change in CCS therapy, and each participant could also change CCS therapy more than once. Therefore, the number of reasons could exceed the number of participants analyzed.

Time frame:
From Baseline to last dose; assessed every 4 weeks during treatment (up to 96 weeks overall)
Reported as:
Number · percentage of reasons
Percentage of Reasons Given for CCS Discontinuation
percentage of reasonsSC TCZ Q2WSC TCZ QW
AE Resolution018.5
AEs50.011.1
Prescription End014.8
RA Improvement014.8
Steroid Tapering50.018.5
Participant Request07.4
Not Specified014.8
SecondaryNumber of Participants Who Switched From the QW Regimen and Remained on the Q2W Regimen

Participants could switch between regimens at the Investigator's judgment based upon safety, efficacy, and pharmacokinetic/pharmacodynamic data. The number of participants who switched from the QW to the Q2W regimen and did not return to the QW regimen was reported.

Time frame:
From Baseline to last dose; assessed every 4 weeks during treatment (up to 96 weeks overall)
Reported as:
Number · participants
Number of Participants Who Switched From the QW Regimen and Remained on the Q2W Regimen
participantsSC TCZ/All Participants
Number of Participants Who Switched From the QW Regimen and Remained on the Q2W Regimen14
SecondaryPercentage of Participants Who Switched From the QW Regimen and Remained on the Q2W Regimen

Participants could switch between regimens at the Investigator's judgment based upon safety, efficacy, and pharmacokinetic/pharmacodynamic data. The percentage of participants who switched from the QW to the Q2W regimen and did not return to the QW regimen was calculated.

Time frame:
From Baseline to last dose; assessed every 4 weeks during treatment (up to 96 weeks overall)
Reported as:
Number · percentage of participants
Percentage of Participants Who Switched From the QW Regimen and Remained on the Q2W Regimen
percentage of participantsSC TCZ/All Participants
Percentage of Participants Who Switched From the QW Regimen and Remained on the Q2W Regimen6.5
SecondaryNumber of Participants Who Returned to the QW Regimen After Switching to the Q2W Regimen

Participants could switch between regimens at the Investigator's judgment based upon safety, efficacy, and pharmacokinetic/pharmacodynamic data. The number of participants who switched from the QW to the Q2W regimen and thereafter returned to the QW regimen was reported with the reason for returning to the QW regimen.

Time frame:
From Baseline to last dose; assessed every 4 weeks during treatment (up to 96 weeks overall)
Reported as:
Number · participants
Number of Participants Who Returned to the QW Regimen After Switching to the Q2W Regimen
participantsSC TCZ/All Participants
Any Reason1
Investigator Recommendation1
SecondaryTime to Return to the QW Regimen After Switching to the Q2W Regimen

Participants could switch between regimens at the Investigator's judgment based upon safety, efficacy, and pharmacokinetic/pharmacodynamic data. Time to return was defined as the time between switching to the Q2W regimen and returning to the previous QW regimen.

Time frame:
From Baseline to last dose; assessed every 4 weeks during treatment (up to 96 weeks overall)
Reported as:
Median · weeks
Time to Return to the QW Regimen After Switching to the Q2W Regimen
weeksSC TCZ/All Participants
Time to Return to the QW Regimen After Switching to the Q2W Regimen20
SecondaryGlobal Assessment of Disease Activity by the Participant According to Visual Analog Scale (VAS) Score

The Global Assessment of Disease Activity was performed using a 100-mm horizontal VAS. Scores may range from 0 mm ("no disease activity") to 100 mm ("maximum disease activity"), with higher scores representing an increase in perceived symptoms.

Time frame:
Baseline and Weeks 12, 24, 36, 48, 60, 72, 84
Reported as:
Mean · mm
Global Assessment of Disease Activity by the Participant According to Visual Analog Scale (VAS) Score
mmSC TCZ Q2WSC TCZ QW
Baseline (n=44,173)39.39 ± 24.48347.25 ± 29.868
Week 12 (n=44,172)31.80 ± 23.87837.84 ± 28.130
Week 24 (n=43,168)31.86 ± 25.63937.51 ± 27.536
Week 36 (n=39,159)30.13 ± 23.34537.44 ± 27.519
Week 48 (n=18,141)37.95 ± 24.87834.63 ± 27.136
Week 60 (n=2,92)54.00 ± 24.04232.86 ± 27.932
Week 72 (n=1,52)57.00 ± NA30.83 ± 28.425
Week 84 (n=0,11)NA ± NA30.00 ± 26.348
SecondaryChange From Baseline in Global Assessment of Disease Activity by the Participant According to VAS Score

The Global Assessment of Disease Activity was performed using a 100-mm horizontal VAS. Scores may range from 0 mm ("no disease activity") to 100 mm ("maximum disease activity"), with higher scores representing an increase in perceived symptoms. The change from Baseline to each visit was calculated, where positive changes represent an increase or worsening in perceived disease activity.

Time frame:
Baseline to Weeks 12, 24, 36, 48, 60, 72, 84
Reported as:
Mean · mm
Change From Baseline in Global Assessment of Disease Activity by the Participant According to VAS Score
mmSC TCZ Q2WSC TCZ QW
Week 12 (n=44,172)-7.59 ± 22.689-9.59 ± 22.348
Week 24 (n=43,168)-6.67 ± 18.977-9.67 ± 26.260
Week 36 (n=39,159)-11.59 ± 23.736-10.14 ± 25.338
Week 48 (n=18,141)-5.61 ± 21.892-11.47 ± 25.839
Week 60 (n=2,92)11.50 ± 30.406-9.93 ± 22.992
Week 72 (n=1,52)19.00 ± NA-13.82 ± 25.779
Week 84 (n=0,11)NA ± NA-10.82 ± 19.778
SecondaryGlobal Assessment of Pain by the Participant According to VAS Score

The Global Assessment of Pain was performed using a 100-mm horizontal VAS. Scores may range from 0 mm ("no pain") to 100 mm ("unbearable pain"), with higher scores representing an increase in pain.

Time frame:
Baseline and Weeks 12, 24, 36, 48, 60, 72, 84
Reported as:
Mean · mm
Global Assessment of Pain by the Participant According to VAS Score
mmSC TCZ Q2WSC TCZ QW
Baseline (n=44,173)36.89 ± 23.04445.42 ± 29.448
Week 12 (n=44,172)29.30 ± 22.78233.27 ± 25.984
Week 24 (n=43,168)29.42 ± 24.50934.48 ± 24.841
Week 36 (n=39,159)28.38 ± 20.60734.40 ± 25.149
Week 48 (n=18,141)33.44 ± 21.74231.52 ± 25.892
Week 60 (n=2,92)50.00 ± 14.14230.94 ± 27.635
Week 72 (n=1,52)42.00 ± NA29.20 ± 26.733
Week 84 (n=0,11)NA ± NA25.36 ± 25.598
SecondaryChange From Baseline in Global Assessment of Pain by the Participant According to VAS Score

The Global Assessment of Pain was performed using a 100-mm horizontal VAS. Scores may range from 0 mm ("no pain") to 100 mm ("unbearable pain"), with higher scores representing an increase in pain. The change from Baseline to each visit was calculated, where positive changes represent an increase or worsening in pain.

Time frame:
Baseline to Weeks 12, 24, 36, 48, 60, 72, 84
Reported as:
Mean · mm
Change From Baseline in Global Assessment of Pain by the Participant According to VAS Score
mmSC TCZ Q2WSC TCZ QW
Week 12 (n=44,172)-7.59 ± 22.145-12.27 ± 21.582
Week 24 (n=43,168)-6.63 ± 20.641-10.76 ± 24.154
Week 36 (n=39,159)-10.62 ± 22.783-10.91 ± 22.747
Week 48 (n=18,141)-8.00 ± 18.166-12.91 ± 24.950
Week 60 (n=2,92)3.00 ± 25.456-10.07 ± 22.001
Week 72 (n=1,52)3.00 ± NA-12.47 ± 23.522
Week 84 (n=0,11)NA ± NA-14.64 ± 20.911
SecondaryHeath Assessment Questionnaire-Disability Index (HAQ-DI) Score

The Stanford HAQ-DI was calculated as the average of 20 questions, each scored from 0 (no difficulty) to 3 (unable to do). The questionnaire included 8 component sets: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and common activities. Overall scores may range from 0 to 3, with higher scores representing increased disability.

Time frame:
Baseline and Weeks 12, 24, 36, 48, 60, 72, 84
Reported as:
Mean · units on a scale
Heath Assessment Questionnaire-Disability Index (HAQ-DI) Score
units on a scaleSC TCZ Q2WSC TCZ QW
Baseline (n=44,173)0.98 ± 0.6821.20 ± 0.729
Week 12 (n=44,172)0.95 ± 0.6881.11 ± 0.750
Week 24 (n=43,167)0.94 ± 0.7171.09 ± 0.725
Week 36 (n=39,159)0.95 ± 0.6821.10 ± 0.741
Week 48 (n=18,141)0.97 ± 0.5961.04 ± 0.745
Week 60 (n=2,92)2.13 ± 0.5301.01 ± 0.779
Week 72 (n=1,52)2.25 ± NA0.97 ± 0.844
Week 84 (n=0,11)NA ± NA1.14 ± 0.730
SecondaryChange From Baseline in HAQ-DI Score

The Stanford HAQ-DI was calculated as the average of 20 questions, each scored from 0 (no difficulty) to 3 (unable to do). The questionnaire included 8 component sets: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and common activities. Overall scores may range from 0 to 3, with higher scores representing increased disability. The change from Baseline to each visit was calculated, where positive changes represent an increased need for assistance with daily activities.

Time frame:
Baseline to Weeks 12, 24, 36, 48, 60, 72, 84
Reported as:
Mean · units on a scale
Change From Baseline in HAQ-DI Score
units on a scaleSC TCZ Q2WSC TCZ QW
Week 12 (n=44,172)-0.02 ± 0.254-0.10 ± 0.339
Week 24 (n=43,167)-0.01 ± 0.272-0.11 ± 0.372
Week 36 (n=39,159)-0.08 ± 0.276-0.09 ± 0.394
Week 48 (n=18,141)-0.01 ± 0.237-0.14 ± 0.390
Week 60 (n=2,92)0.56 ± 0.795-0.08 ± 0.394
Week 72 (n=1,52)0.88 ± NA-0.06 ± 0.420
Week 84 (n=0,11)NA ± NA-0.07 ± 0.397
SecondaryPercentage of Participants With HAQ-DI Score <0.5

The Stanford HAQ-DI was calculated as the average of 20 questions, each scored from 0 (no difficulty) to 3 (unable to do). The questionnaire included 8 component sets: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and common activities. Overall scores may range from 0 to 3, with higher scores representing increased disability. The percentage of participants achieving a score \<0.5 was calculated at each visit.

Time frame:
Baseline and Weeks 12, 24, 36, 48, 60, 72, 84
Reported as:
Number · percentage of participants
Percentage of Participants With HAQ-DI Score <0.5
percentage of participantsSC TCZ Q2WSC TCZ QW
Baseline (n=44,173)31.817.9
Week 12 (n=44,172)27.320.9
Week 24 (n=43,167)32.623.4
Week 36 (n=39,159)38.524.5
Week 48 (n=18,141)27.824.8
Week 60 (n=2,92)0.029.3
Week 72 (n=1,52)0.034.6
Week 84 (n=0,11)NA9.1
SecondaryNumber of Participants With Low Disease Activity According to DAS28, SDAI, and CDAI Criteria

Low disease activity was defined as DAS28 ≤3.2, SDAI ≤11, or CDAI ≤10. For each formula, the SJC and TJC values were based upon 28 joints, and VAS was transformed from a 100-mm scale to a 10-point score. The DAS28 was calculated as (0.56 × square root of TJC) + (0.28 × square root of SJC) + (0.7 × ln ESR) + (0.014 × VAS), with potential scores from 0 to 10. The SDAI was calculated as SJC + TJC + VAS (participant) + VAS (physician) + hsCRP, with potential scores from 0 to infinity. However, based upon normal hsCRP level within 1 mg/dL, scores would be expected to fall within ≤77 points. The CDAI was calculated as SJC + TJC + VAS (participant) + VAS (physician), with potential scores from 0 to 76. For all instruments, higher scores indicate increased disease activity. The number of participants who met criteria for low disease activity was reported at each visit.

Time frame:
Baseline and Weeks 12, 24, 36, 48, 60, 72, 84
Reported as:
Number · participants
Number of Participants With Low Disease Activity According to DAS28, SDAI, and CDAI Criteria
participantsSC TCZ Q2WSC TCZ QW
Baseline, DAS28 (n=44,172)1146
Baseline, SDAI (n=44,170)1443
Baseline, CDAI (n=44,173)1341
Week 12, DAS28 (n=44,172)2181
Week 12, SDAI (n=44,172)2265
Week 12, CDAI (n=44,172)2063
Week 24, DAS28 (n=43,168)2382
Week 24, SDAI (n=41,166)1967
Week 24, CDAI (n=42,166)2060
Week 36, DAS28 (n=39,159)2175
Week 36, SDAI (n=39,159)2061
Week 36, CDAI (n=39,159)2160
Week 48, DAS28 (n=18,141)1069
Week 48, SDAI (n=18,140)863
Week 48, CDAI (n=18,140)759
Week 60, DAS28 (n=2,92)052
Week 60, SDAI (n=2,92)040
Week 60, CDAI (n=2,92)037
Week 72, DAS28 (n=1,52)028
Week 72, SDAI (n=1,52)026
Week 72, CDAI (n=1,52)025
Week 84, DAS28 (n=0,11)NA6
Week 84, SDAI (n=0,11)NA4
Week 84, CDAI (n=0,11)NA4
SecondaryPercentage of Participants With Low Disease Activity According to DAS28, SDAI, and CDAI Criteria

Low disease activity was defined as DAS28 ≤3.2, SDAI ≤11, or CDAI ≤10. For each formula, the SJC and TJC values were based upon 28 joints, and VAS was transformed from a 100-mm scale to a 10-point score. The DAS28 was calculated as (0.56 × square root of TJC) + (0.28 × square root of SJC) + (0.7 × ln ESR) + (0.014 × VAS), with potential scores from 0 to 10. The SDAI was calculated as SJC + TJC + VAS (participant) + VAS (physician) + hsCRP, with potential scores from 0 to infinity. However, based upon normal hsCRP level within 1 mg/dL, scores would be expected to fall within ≤77 points. The CDAI was calculated as SJC + TJC + VAS (participant) + VAS (physician), with potential scores from 0 to 76. For all instruments, higher scores indicate increased disease activity. The percentage of participants who met criteria for low disease activity was calculated at each visit.

Time frame:
Baseline and Weeks 12, 24, 36, 48, 60, 72, 84
Reported as:
Number · percentage of participants
Percentage of Participants With Low Disease Activity According to DAS28, SDAI, and CDAI Criteria
percentage of participantsSC TCZ Q2WSC TCZ QW
Baseline, DAS28 (n=44,172)25.026.7
Baseline, SDAI (n=44,170)31.825.3
Baseline, CDAI (n=44,173)29.523.7
Week 12, DAS28 (n=44,172)47.747.1
Week 12, SDAI (n=44,172)50.037.8
Week 12, CDAI (n=44,172)45.536.6
Week 24, DAS28 (n=43,168)53.548.8
Week 24, SDAI (n=41,166)46.340.4
Week 24, CDAI (n=42,166)47.636.1
Week 36, DAS28 (n=39,159)53.847.2
Week 36, SDAI (n=39,159)51.338.4
Week 36, CDAI (n=39,159)53.837.7
Week 48, DAS28 (n=18,141)55.648.9
Week 48, SDAI (n=18,140)44.445.0
Week 48, CDAI (n=18,140)38.942.1
Week 60, DAS28 (n=2,92)0.056.5
Week 60, SDAI (n=2,92)0.043.5
Week 60, CDAI (n=2,92)0.040.2
Week 72, DAS28 (n=1,52)0.053.8
Week 72, SDAI (n=1,52)0.050.0
Week 72, CDAI (n=1,52)0.048.1
Week 84, DAS28 (n=0,11)NA54.5
Week 84, SDAI (n=0,11)NA36.4
Week 84, CDAI (n=0,11)NA36.4
SecondaryNumber of Participants With Remission According to DAS28, SDAI, and Boolean Criteria

Remission was defined as DAS28 \<2.6, SDAI ≤3.3, or meeting all Boolean criteria (28-count SJC and TJC ≤1, VAS ≤10 mm, and hsCRP ≤1 mg/dL). For DAS28 and SDAI formulas, the SJC and TJC values were based upon 28 joints, and VAS was transformed from a 100-mm scale to a 10-point score. The DAS28 was calculated as (0.56 × square root of TJC) + (0.28 × square root of SJC) + (0.7 × ln ESR) + (0.014 × VAS), with potential scores from 0 to 10. The SDAI was calculated as SJC + TJC + VAS (participant) + VAS (physician) + hsCRP, with potential scores from 0 to infinity. However, based upon normal hsCRP level within 1 mg/dL, scores would be expected to fall within ≤77 points. For these instruments, higher scores indicate increased disease activity. The number of participants who met criteria for remission was reported at each visit.

Time frame:
Baseline and Weeks 12, 24, 36, 48, 60, 72, 84
Reported as:
Number · participants
Number of Participants With Remission According to DAS28, SDAI, and Boolean Criteria
participantsSC TCZ Q2WSC TCZ QW
Baseline, DAS28 (n=44,172)633
Baseline, SDAI (n=44,170)215
Baseline, Boolean (n=44,172)114
Week 12, DAS28 (n=44,172)1461
Week 12, SDAI (n=44,172)720
Week 12, Boolean (n=44,172)415
Week 24, DAS28 (n=43,168)1861
Week 24, SDAI (n=41,166)823
Week 24, Boolean (n=43,170)516
Week 36, DAS28 (n=39,159)1557
Week 36, SDAI (n=39,159)721
Week 36, Boolean (n=39,161)317
Week 48, DAS28 (n=18,141)951
Week 48, SDAI (n=18,140)115
Week 48, Boolean (n=18,143)114
Week 60, DAS28 (n=2,92)039
Week 60, SDAI (n=2,92)017
Week 60, Boolean (n=2,93)014
Week 72, DAS28 (n=1,52)022
Week 72, SDAI (n=1,52)011
Week 72, Boolean (n=1,54)010
Week 84, DAS28 (n=0,11)NA6
Week 84, SDAI (n=0,11)NA2
Week 84, Boolean (n=0,11)NA2
SecondaryPercentage of Participants With Remission According to DAS28, SDAI, and Boolean Criteria

Remission was defined as DAS28 \<2.6, SDAI ≤3.3, or meeting all Boolean criteria (28-count SJC and TJC ≤1, VAS ≤10 mm, and hsCRP ≤1 mg/dL). For DAS28 and SDAI formulas, the SJC and TJC values were based upon 28 joints, and VAS was transformed from a 100-mm scale to a 10-point score. The DAS28 was calculated as (0.56 × square root of TJC) + (0.28 × square root of SJC) + (0.7 × ln ESR) + (0.014 × VAS), with potential scores from 0 to 10. The SDAI was calculated as SJC + TJC + VAS (participant) + VAS (physician) + hsCRP, with potential scores from 0 to infinity. However, based upon normal hsCRP level within 1 mg/dL, scores would be expected to fall within ≤77 points. For these instruments, higher scores indicate increased disease activity. The percentage of participants who met criteria for remission was calculated at each visit.

Time frame:
Baseline and Weeks 12, 24, 36, 48, 60, 72, 84
Reported as:
Number · percentage of participants
Percentage of Participants With Remission According to DAS28, SDAI, and Boolean Criteria
percentage of participantsSC TCZ Q2WSC TCZ QW
Baseline, DAS28 (n=44,172)13.619.2
Baseline, SDAI (n=44,170)4.58.8
Baseline, Boolean (n=44,172)2.38.1
Week 12, DAS28 (n=44,172)31.835.5
Week 12, SDAI (n=44,172)15.911.6
Week 12, Boolean (n=44,172)9.18.7
Week 24, DAS28 (n=43,168)41.936.3
Week 24, SDAI (n=41,166)19.513.9
Week 24, Boolean (n=43,170)11.69.4
Week 36, DAS28 (n=39,159)38.535.8
Week 36, SDAI (n=39,159)17.913.2
Week 36, Boolean (n=39,161)7.710.6
Week 48, DAS28 (n=18,141)50.036.2
Week 48, SDAI (n=18,140)5.610.7
Week 48, Boolean (n=18,143)5.69.8
Week 60, DAS28 (n=2,92)0.042.4
Week 60, SDAI (n=2,92)0.018.5
Week 60, Boolean (n=2,93)0.015.1
Week 72, DAS28 (n=1,52)0.042.3
Week 72, SDAI (n=1,52)0.021.2
Week 72, Boolean (n=1,54)0.018.5
Week 84, DAS28 (n=0,11)NA54.5
Week 84, SDAI (n=0,11)NA18.2
Week 84, Boolean (n=0,11)NA18.2

Adverse events

Collected over From Baseline to 8 weeks after last dose; assessed continuously during treatment (up to 96 weeks) and up to 8 weeks after last dose (up to 2 years overall). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
SC TCZ Q2W—4/44 (9.1%)22/44 (50%)
SC TCZ QW—19/173 (11%)102/173 (59%)
Most frequent serious events
Showing 10 of 31
Most frequent serious events
EventSC TCZ Q2WSC TCZ QW
EndophthalmitisInfections and infestations1/440/173
PyelonephritisInfections and infestations1/440/173
SyncopeNervous system disorders1/441/173
Abdominal compartment syndromeGastrointestinal disorders1/440/173
Deep vein thrombosisVascular disorders1/440/173
Endometrial stromal sarcomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/440/173
HaematuriaRenal and urinary disorders1/440/173
CellulitisInfections and infestations0/442/173
Staphylococcal bacteraemiaInfections and infestations0/442/173
Transient ischaemic attackNervous system disorders0/442/173
Most frequent other events
Showing 10 of 13
Most frequent other events
EventSC TCZ Q2WSC TCZ QW
Upper respiratory tract infectionInfections and infestations8/4435/173
SinusitisInfections and infestations2/4422/173
NasopharyngitisInfections and infestations2/4420/173
Urinary tract infectionInfections and infestations2/4415/173
ArthralgiaMusculoskeletal and connective tissue disorders2/4412/173
Alanine aminotransferase increasedInvestigations0/4412/173
FallInjury, poisoning and procedural complications3/446/173
ContusionInjury, poisoning and procedural complications3/445/173
DiarrhoeaGastrointestinal disorders3/448/173
RashSkin and subcutaneous tissue disorders3/446/173

Baseline characteristics

Safety Population: All participants who received at least one dose of study medication and had at least one post-dose safety assessment.

Age, Continuous
Age, Continuous(years)SC TCZ Q2WSC TCZ QWTotal
Mean59.7 ± 10.1858.1 ± 10.3858.4 ± 10.33
Sex: Female, Male
Sex: Female, Male(Participants)SC TCZ Q2WSC TCZ QWTotal
Female33133166
Male114051
08

Study locations

79 sites
  • Tuscaloosa, Alabama 35406, United States
  • Peoria, Arizona 85381, United States
  • Scottsdale, Arizona 85258, United States
  • Tucson, Arizona 85704, United States
  • Tucson, Arizona 85715, United States
  • Tucson, Arizona 85723, United States
  • Tucson, Arizona 85724, United States
  • Fullerton, California 92835, United States
  • Long Beach, California 90806, United States
  • Los Angeles, California 90048, United States
  • San Diego, California 92108, United States
  • San Leandro, California 94578, United States
  • Upland, California 91786, United States
  • Van Nuys, California 91405, United States
  • West Hills, California 91307, United States
  • Whittier, California 90606, United States
  • Denver, Colorado 80230-7127, United States
  • Bridgeport, Connecticut 06606, United States
  • Trumbull, Connecticut 06611, United States
  • Jupiter, Florida 33458, United States
  • Orlando, Florida 32806, United States
  • Palm Harbor, Florida 34684, United States
  • South Miami, Florida 33143, United States
  • Tampa, Florida 33614, United States
  • Venice, Florida 34233, United States
  • Gainesville, Georgia 30501, United States
  • Coeur D'alene, Idaho 83814, United States
  • Idaho Falls, Idaho 83404, United States
  • Meridian, Idaho 83642, United States
  • Morton Grove, Illinois 60053, United States
  • Springfield, Illinois 62703, United States
  • Vernon Hills, Illinois 60061, United States
  • Wichita, Kansas 67208, United States
  • Monroe, Louisiana 71203, United States
  • Hagerstown, Maryland 21740, United States
  • Wheaton, Maryland 20902, United States
  • Worcester, Massachusetts 01605, United States
  • St. Claire Shores, Michigan 48081, United States
  • Eagan, Minnesota 55121, United States
  • Flowood, Mississippi 39232, United States
  • Jackson, Mississippi 39202, United States
  • Florissant, Missouri 63031, United States
  • Saint Louis, Missouri 63117, United States
  • Saint Louis, Missouri 63141, United States
  • Lincoln, Nebraska 68516, United States
  • Lebanon, New Hampshire 03756, United States
  • Clifton, New Jersey 07012, United States
  • Freehold, New Jersey 07728, United States
  • Manalapan, New Jersey 07726, United States
  • Voorhees, New Jersey 08043, United States
  • Albuquerque, New Mexico 87102, United States
  • Albany, New York 12206, United States
  • Brooklyn, New York 11201, United States
  • Orchard Park, New York 14127, United States
  • Asheville, North Carolina 28803, United States
  • Charlotte, North Carolina 28210, United States
  • Raleigh, North Carolina 27615, United States
  • Wilmington, North Carolina 28401, United States
  • Cincinnati, Ohio 45219, United States
  • Perrysburg, Ohio 43551, United States
  • Toledo, Ohio 43606, United States
  • Oklahoma City, Oklahoma 73103, United States
  • Oklahoma City, Oklahoma 73104, United States
  • Tulsa, Oklahoma 74135, United States
  • Bethlehem, Pennsylvania 18015, United States
  • Duncansville, Pennsylvania 16635, United States
  • Wyomissing, Pennsylvania 19610, United States
  • Charleston, South Carolina 29407, United States
  • Knoxville, Tennessee 37909, United States
  • Memphis, Tennessee 38104, United States
  • Memphis, Tennessee 38119, United States
  • Houston, Texas 77004, United States
  • Houston, Texas 77074, United States
  • Nassau Bay, Texas 77058, United States
  • Olympia, Washington 98502, United States
  • Seattle, Washington 98104, United States
  • Spokane, Washington 99204, United States
  • Wenatchee, Washington 98801, United States
  • Ponce, 00716, Puerto Rico
09

References and documents

Publications

  • Kivitz A, Wallace T, Olech E, Borofsky M, Devenport J, Pei J, Michalska M. Long-Term Safety and Efficacy of Subcutaneously Administered Tocilizumab for Adult Rheumatoid Arthritis: A Multicenter Phase 3b Long-term Extension Study. Rheumatol Ther. 2016 Dec;3(2):291-304. doi: 10.1007/s40744-016-0043-1. Epub 2016 Sep 24. PubMed 27747585 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2012, a primary completion of Apr 2014 and a completion of Jun 2014. It does not say whether these dates are actual or estimated.

Results were first posted in Oct 2016, 2 years 6 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 30, 2012
First posted
Aug 10, 2012
Start
Aug 2012
Primary completionActual
Apr 2014
CompletionActual
Jun 2014
Results first posted
Oct 12, 2016
Last update
Oct 12, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 12, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01662063
Lead sponsor
Genentech, Inc.
Responsible party
Sponsor
First posted
Aug 10, 2012
Start date
Aug 2012
Primary completion
Apr 2014
Completion
Jun 2014
Results posted
Oct 12, 2016
Last update
Oct 12, 2016

Study contacts

Clinical Trials
study director · Genentech, Inc.
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tocilizumab

Start the discussion